Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
Monotherapy
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "Monotherapy" in MCE Product Catalog:
Cat. No.: HY-159644
CAS No.: 2709069-30-5
Synonyms: AB521
Target:
Research Areas:
Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
Cat. No.: HY-N6579
CAS No.: 65247-27-0
Target:
Target:
Research Areas:
CHK1-IN-3 is a potent and selective CHK1 inhibitor with an IC50 of 0.4 nM. CHK1-IN-3 effectively inhibits the growth of malignant hematopathy cell lines and displays low affinity for hERG (IC50 > 40 μM). CHK1-IN-3 significantly suppresses the tumor growth in vivo. CHK1-IN-3 can be used for the study of hematologic malignancies .
Cat. No.: HY-P990067
CAS No.: 2639688-77-8
Synonyms: ATOR-1017
Target:
Research Areas:
Cat. No.: HY-178716
CAS No.: 3093350-55-8
Target:
Research Areas:
PTPN2/1-IN-4 (Compound WS35) is an orally active, dual-functional inhibitor of PTPN1 and PTPN2 with IC50s of 12.8 and 5.8 nM for PTPN1 and PTPN2, respectively. PTPN2/1-IN-4 modulates the IFNγ-JAK-STAT signaling pathway and significantly augments CD8+ T-cell tumor infiltration. PTPN2/1-IN-4 has potent anticancer activity, robustly inhibiting tumor growth both as a monotherapy and in combination with an anti-PD-1 antibody in B16-OVA syngeneic mouse models .
Cat. No.: HY-159707
CAS No.: 2309309-69-9
Target:
Research Areas:
MCL1020 is a CHK1 inhibitor with an IC50 of 1.61 μM. MCL1020 properly occupies the ATP pocket by interacting with a diverse range of the sites of CHK1 kinase. MCL1020 can be used for the study of hematologic malignancies .
Cat. No.: HY-174377
Target:
Androgen Receptor p38 MAPK Caspase Cytochrome P450 Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Mitochondrial Metabolism GLUT
Research Areas:
PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors .
Cat. No.: HY-183476
CAS No.: 36508-71-1
Synonyms: Rubidazon hydrochloride; Rubidazone hydrochloride
Target:
Zorubicin hydrochloride is an anthracycline Antibiotic. Zorubicin hydrochloride exhibits activity against breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma. Zorubicin hydrochloride shows activity against undifferentiated nasopharyngeal carcinoma either as a monotherapy or in combination with Cisplatin (HY-17394). Zorubicin hydrochloride can be used in research related to breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma .
Cat. No.: HY-183631
CAS No.: 2248127-86-6
PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors .
Cat. No.: HY-184213
CAS No.: 2408260-34-2
Target:
Research Areas:
INCB106385 is an orally active A2A/A2B adenosine receptor antagonist, with an IC50 value of 4.4 nM for cAMP inhibition at the A2A adenosine receptor and an IC50 value of 6.4 nM for cAMP inhibition at the A2B adenosine receptor. INCB106385 inhibits the pCREB signaling pathway in immune cells, blocks adenosine-mediated immunosuppression in the tumor microenvironment, and induces tumor regression. INCB106385 exhibits efficacy as a monotherapy or in combination with anti-PD-1 antibodies in colon cancer models. INCB106385 can be used for the research of colon cancer .
Cat. No.: HY-P992454
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
